Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 21 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

9 recruiting

Enrollment Performance

Analytics

Early Phase 1

8(38.1%)

Phase 1

7(33.3%)

N/A

5(23.8%)

Phase 4

1(4.8%)

21Total

Early Phase 1(8)

Phase 1(7)

N/A(5)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials

NCT06709131Phase 1Suspended

A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia

Role: lead

NCT06120166Early Phase 1Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Role: lead

NCT06902025Not ApplicableNot Yet Recruiting

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia

Role: lead

NCT06887985Not ApplicableNot Yet Recruiting

JY231(JY231) Injection for the Treatment of Refractory Autoimmune Diseases (ADs)

Role: lead

NCT06879470Not ApplicableNot Yet Recruiting

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma

Role: lead

NCT06162338Not ApplicableRecruiting

A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients with Gaucher Disease Type I

Role: lead

NCT06809712Phase 1Recruiting

Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

Role: lead

NCT06809699Phase 1Recruiting

Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation

Role: lead

NCT04689204Early Phase 1Completed

A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies

Role: lead

NCT06785519Early Phase 1Recruiting

CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis

Role: lead

NCT05716113Early Phase 1Completed

CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL

Role: lead

NCT06571825Phase 4Recruiting

RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR

Role: lead

NCT06084962Phase 1Recruiting

A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Role: lead

NCT05444322Early Phase 1Unknown

A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Role: lead

NCT05340829Phase 1Unknown

Evaluate the Safety and Effect of ThisCART19A in Patients With AIDS Related B Cell Lymphoma/Lympholeukemia

Role: lead

NCT04538599Phase 1Completed

RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies

Role: lead

NCT04227015Early Phase 1Recruiting

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Role: lead

NCT04626908Phase 1Unknown

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Role: lead

NCT04283006Early Phase 1Recruiting

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

Role: lead

NCT04448509Not ApplicableUnknown

Peripheral Blood Mononuclear Cell Collection Protocol for UCART Cell Tumor Immunotherapy Study

Role: lead